Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes
Open Orphan PLC (ORPH.L) New Contract win for Breda office & COVID-19 Programme update
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces
Open Orphan PLC (ORPH.L) HRV and Flu contract
Significant HRV & Influenza human challenge study contract win
Open Orphan PLC (ORPH.L) Demerger Update
Further to Open Orphan’s announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention
Open Orphan PLC (ORPH.L) Re. Distribution in Specie and Notice of Results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials ,
Open Orphan PLC (ORPH.L) Exercise of Warrants
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials.
Open Orphan PLC (ORPH.L) Court Approval to facilitate Distribution in Specie
Continued progress towards planned Demerger
Open Orphan PLC (ORPH.L) £3m COVID challenge virus manufacturing contract
hVIVO to develop challenge agent based on new COVID-19 variants
Open Orphan PLC (ORPH.L) Potential demerger of certain non-core assets
Proposed Capital Reduction, Distribution in Specie and notice of General Meeting
Open Orphan PLC (ORPH.L) Launch of Disease in Motion platform
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces
Open Orphan PLC (ORPH.L) £7.5m Human Challenge Study Contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials.
Open Orphan PLC (ORPH.L) COVID-19 Human Challenge Programme update
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces